Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics
Authors:
Open Access
- 7 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 972301
Abstract
All muscle contraction occurs due to the cyclical interaction between sarcomeric thin and thick filament proteins within the myocyte. The thin filament consists of the proteins actin, tropomyosin, Troponin C, Troponin I, and Troponin T. Mutations in these proteins can result in various forms of cardiomyopathy, including hypertrophic, restrictive, and dilated phenotypes and account for as many as 30% of all cases of inherited cardiomyopathy. There is significant evidence that thin filament mutations contribute to dysregulation of Ca2+ within the sarcomere and may have a distinct pathomechanism of disease from cardiomyopathy associated with thick filament mutations. A number of distinct clinical findings appear to be correlated with thin-filament mutations: greater degrees of restrictive cardiomyopathy and relatively less left ventricular (LV) hypertrophy and LV outflow tract obstruction than that seen with thick filament mutations, increased morbidity associated with heart failure, increased arrhythmia burden and potentially higher mortality. Most therapies that improve outcomes in heart failure blunt the neurohormonal pathways involved in cardiac remodeling, while most therapies for hypertrophic cardiomyopathy involve use of negative inotropes to reduce LV hypertrophy or septal reduction therapies to reduce LV outflow tract obstruction. None of these therapies directly address the underlying sarcomeric dysfunction associated with thin-filament mutations. With mounting evidence that thin filament cardiomyopathies occur through a distinct mechanism, there is need for therapies targeting the unique, underlying mechanisms tailored for each patient depending on a given mutation.Keywords
This publication has 201 references indexed in Scilit:
- Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in miceEMBO Molecular Medicine, 2013
- Genetic Testing for Dilated Cardiomyopathy in Clinical PracticeJournal of Cardiac Failure, 2012
- Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling proteinJournal of Molecular and Cellular Cardiology, 2011
- Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathyNetherlands Heart Journal, 2011
- Several cardiomyopathy causing mutations on tropomyosin either destabilize the active state of actomyosin or alter the binding properties of tropomyosinBiochemical and Biophysical Research Communications, 2011
- Enhanced Active Cross-Bridges during Diastole: Molecular Pathogenesis of Tropomyosin's HCM MutationsBiophysical Journal, 2011
- Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- What makes tropomyosin an actin binding protein? A perspectiveJournal of Structural Biology, 2010
- Human actin mutations associated with hypertrophic and dilated cardiomyopathies demonstrate distinct thin filament regulatory properties in vitroJournal of Molecular and Cellular Cardiology, 2010
- Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutantsJournal of Molecular and Cellular Cardiology, 2008